



Vaccines and Global Health: The Week in Review
09 March 2024 :: Issue 741
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives

.....
.....

[WHO - Strategic Advisory Group of Experts on Immunization \(SAGE\) - March 2024](#)

11 – 14 March 2024 Geneva

[SAGE Yellow Book for March 2024](#)

[Draft agenda](#)

- Global and regional reports – Session 1
- IA2030 deep dive – Session 2
- Polio – Session 3
- Hepatitis E – Session 4
- COVID-19 – Session 5
- Mpox – Session 6
- Immune correlates – Session 7
- RSV – Session 8

.....

[Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - February 2024](#)

8 March 2024 Departmental news

.....
.....

[Gavi – Vaccine Alliance outlines path to improve HPV vaccine market](#)

- A **new Gavi market shaping roadmap for HPV vaccines** showcases how partners, manufacturers and countries must work together to secure a sustainable supply over the next decade.
- The action plan outlines how this can be achieved by **improving the predictability of demand, a competitive supplier base, and closely monitoring and responding to countries’ needs**.
- Aurélia Nguyen, Chief Programme Officer at Gavi: “Lower-income countries have missed out on HPV vaccines for far too long. To ensure we reach our goal of protecting 86 million girls by 2025, it’s vital that our current supply of doses is managed carefully, and we have donor and manufacturer support to go further and protect more girls.”

Geneva, 8 March 2024 – More adolescent girls across the world will be able to access the human papillomavirus (HPV) vaccine, thanks to proactive efforts from the Vaccine Alliance and manufacturers, which have led to increasing supply. According to projections outlined in a [new insight paper](#) published by Gavi, the Vaccine Alliance, overall HPV vaccine supply is expected to increase, and demand could be met in 2025. However, careful planning will be needed in 2024. Developed in consultation with a range of key Alliance partners, the **Gavi market shaping roadmap for HPV vaccines also showcases how partners, manufacturers and countries must work together to secure a sustainable pipeline of supply over the next decade.**

“Lower-income countries have missed out on HPV vaccines for far too long. To ensure we reach our goal of protecting 86 million girls by 2025, it’s vital that our current supply of doses is managed carefully, and we have donor and manufacturer support to go further and protect more girls.” said Aurélia Nguyen, Chief Programme Officer at Gavi. “With an increase in the number of suppliers and the WHO SAGE one-dose recommendation, **Gavi is urgently acting on these opportunities**, collaborating with partners and countries to scale up access, while equally driving efforts to ensure there is a sustainable supply of HPV vaccines – now, and in the future.”

For over a decade, Gavi has been working to address historical supply challenges while supporting countries to protect 16.3 million adolescent girls with the HPV vaccine. However, these challenges, combined with barriers to accessing the HPV vaccine and the COVID-19 pandemic, led to a **concerning drop in coverage of the HPV vaccine across lower-income countries.** Coverage in 2022 surpassed pre-pandemic levels at 21% for one dose, but it is still well below ideal levels; and the majority of the world’s unprotected girls are in lower-income Gavi implementing countries...

To achieve its vision of a healthy vaccine market, **Gavi has highlighted four key market objectives**, each of which is underpinned by target outcomes:

:: **supply meets demand** to support HPV vaccine programme implementation;

:: **predictability of medium- to long-term demand** is enhanced to facilitate secure supply of affordable vaccines;

:: **diversity of products** suitable for different country contexts is achieved with healthy competition between suppliers; and

:: **future innovations** for potentially new HPV vaccines are accommodated – such as vaccine microarray patches (MAPs) that are applied to the skin to painlessly deliver a vaccine...

.....

[Wave of New Commitments Marks Historic Step Towards the Elimination of Cervical Cancer](#)

New country, policy and program commitments, plus nearly US\$600 million in new funding, at first-ever global forum offer a chance to save hundreds of thousands of lives by 2030.

CARTAGENA DE INDIAS, COLOMBIA (March 5, 2024) – Governments, donors, multilateral institutions, and partners today announced major new policy, programmatic and financial commitments, including nearly US\$600 million in new funding, to eliminate cervical cancer. If these ambitions to expand vaccine coverage and strengthen screening and treatment programs are fully realized, the world could eliminate a cancer for the first time.

These commitments were made at the first-ever *Global Cervical Cancer Elimination Forum: Advancing the Call to Action* in Cartagena de Indias, Colombia, to catalyze national and global momentum to end this preventable disease...

The commitments announced at the forum mark a watershed moment to accelerate progress on a promise made in 2020, when 194 countries adopted WHO’s global strategy to eliminate cervical cancer.

“We have the knowledge and the tools to make cervical cancer history, but vaccination, screening and treatment programmes are still not reaching the scale required,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “This first global forum is an important opportunity for governments and partners to invest in the global elimination strategy and addressing the inequities that deny women and girls’ access to the life-saving tools they need.”

...The nearly US\$600 million in new funding includes US\$180 million from the Bill & Melinda Gates Foundation, US\$10 million from UNICEF, and US\$400 million from the World Bank. A full list and description of commitments can be found [here](#) and will be updated throughout the forum...



Global cervical cancer elimination forum: advancing the call to action

The “Global cervical cancer elimination forum: advancing the call to action” will be held from 5 to 7 March 2024, in Cartagena de Indias, Colombia.

The Forum aims to catalyse governments, donors, civil society, and others to commit to cervical cancer elimination and galvanize the global community.

Every year, cervical cancer continues to impact hundreds of thousands of women, families, and communities, even though we have all the tools we need to prevent it and even eliminate it completely. Access to vaccines, screening and treatment continues to be scarce in the places that need them most. Vaccines prevent human papillomavirus (HPV) infections, in turn preventing cervical cancer and other HPV-related cancers.

WHO’s Global Strategy for Cervical Cancer Elimination, launched on 17 November 2020, lays out a clear path to eliminating the disease through vaccination, screening and treatment. New evidence for a single-dose vaccine, and updated recommendations to simplify and increase access to screening and treatment, will reduce barriers to implementing WHO’s strategy.

The strategy sets out 3 clear targets to meet by 2030 to put countries on the path to elimination:

:: 90% of girls vaccinated against HPV by age 15

:: 70% of women screened with a high-performance test by age 35 and again at 45

:: 90% of women with cervical disease receiving treatment

Annual deaths from cervical cancer will likely reach 410 000 by 2030 if we do not change course. This forum aims to be a pivotal moment and a historic first step in securing government commitments to eliminate, for the first time ever, a full category of cancer on a global scale.

[List of commitments available here](#)

Organizing partners

Government of Colombia

Government of Spain

Bill & Melinda Gates Foundation

Gavi, the Vaccine Alliance

Global Financing Facility

Pan American Health Organization (PAHO)

UNICEF

United States Agency for International Development (USAID)

Unitaid

World Bank

World Health Organization



Announcing 2023 Michelson Prize Laureates – Human Immunome Project

Three early career scientists, Dr. Siyuan Ding, Dr. Claire Otero, and Dr. Dennis Schaefer-Babajew, to receive \$150,000 Grants for immunology and vaccine research.

NEW YORK, March 5, 2024 – The Human Immunome Project and Michelson Medical Research Foundation (MMRF) have awarded **Dr. Siyuan Ding (Washington University in St. Louis), Dr. Claire Otero (Weill Cornell Medicine), and Dr. Dennis Schaefer-Babajew (Rockefeller University)** the Michelson Prizes: Next Generation Grants, the organizations announced today.

The \$150,000 research grants are awarded annually to support early-career scientists advancing human immunology, vaccine discovery, and immunotherapy research for major global diseases.

“Understanding and harnessing the human immune system is the next frontier in biomedicine. Already, breakthrough research in immunology has led to therapies that treat disease, improve human health, and save lives,” said Dr. Gary K. Michelson, founder, and co-chair of Michelson Philanthropies. “Catalytic and flexible philanthropic support helps to fund our brightest young minds to develop high-risk, high-impact science and enable future breakthroughs.”

The three recipients were selected by a distinguished committee of internationally recognized scientists and represent the next generation of innovators in human immunology and vaccine research. Their proposals were chosen based on their novelty and potential impact to accelerate vaccine design and delivery for major diseases.

“We are thrilled to support these researchers as they work on new and cutting-edge approaches to combat deadly and debilitating diseases,” said Dr. Hans Keirstead, CEO of the Human Immunome Project. “The Michelson Prizes: Next Generation Grants are uniquely positioned to advance the field of immunology by supporting the sector’s emerging leaders. I am eager to watch their progress and see the outcomes of their award-winning research.”

Dr. Ding, Dr. Otero, and Dr. Schaefer-Babajew are the **sixth class of Michelson Prize laureates** and will be honored at a virtual award ceremony in collaboration with the Keystone Symposia, to be announced later in the year...

.....
.....
.....

Polio – PHEIC

Polio this week as of 06 Mar 2024 - GPEI

Headlines

:: The Department of Polio Eradication of the World Health Organization (WHO) is seeking experts to serve as members of the Containment Working Group (CWG) of the Global Commission for the Certification of Eradication of Poliomyelitis (GCC). Please [see here](#) for information on how to apply.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: three WPV1-positive environmental samples
- Angola: one cVDPV2-positive environmental sample
- Chad: one cVDPV2 case
- Côte d’Ivoire: nine cVDPV2-positive environmental samples
- Guinea: one cVDPV2 case and one positive environmental sample

- Liberia: one cVDPV2-positive environmental sample
- Mali: three cVDPV2 cases
- Nigeria: eight cVDPV2 cases and seven positive environmental samples
- Somalia: three cVDPV2 cases

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

WHO & Regional Offices [to 09 Mar 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

8 March 2024 Departmental news

[Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - February 2024](#)

7 March 2024 Departmental news

[WHO launches a mobile app for biosafety risk assessment](#)

6 March 2024 News release

[African health ministers commit to end malaria deaths](#)

6 March 2024 Departmental news

[World TB Day 2024 Campaign: YES! WE CAN #ENDTB!](#)

5 March 2024 News release

[Wave of new commitments marks historic step towards the elimination of cervical cancer](#)

5 March 2024 News release

[New report documents increase in HIV drug resistance to dolutegravir](#)

4 March 2024 Departmental news

[Announcing new initiatives to maximize efficiencies of medicine donation programmes for neglected tropical diseases](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 07 March 2024

[More than 2.1 million people vaccinated against cholera in Zimbabwe hotspots](#)

:: 06 March 2024

[**African health ministers commit to end malaria deaths**](#)

WHO Region of the Americas PAHO

:: [**International Women's Day: PAHO Director calls for investment in women's leadership to transform the health sector**](#)

Washington, DC, March 8, 2024 (PAHO)- Even though women make up 70% of health and care sector workers worldwide, barely 25% occupy leadership positions. At an event to mark International Women's Day, the Director of the Pan American Health Organization (PAHO), Jarbas Barbosa, called for greater support to women's leadership while strengthening the...

:: [**Wave of new commitments marks historic step towards the elimination of cervical cancer**](#)

New country, policy and program commitments, plus nearly US\$ 600 million in new funding, at first-ever global forum offer a chance to save hundreds of thousands of lives by 2030. Cartagena de Indias, Colombia, 5 March 2024 — Governments, donors, multilateral institutions, and partners today announced major new policy, programmatic and financial...

WHO South-East Asia Region SEARO

:: 5 March 2024 News release

[**WHO rolls out universal newborn screening implementation guidance in South-East Asia Region**](#)

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: [**WHO and Ministry of Health digitize information vital for a healthier Iraq**](#)

7 March 2024

:: [**Towards a stronger commitment to eliminate malaria in Sudan**](#)

7 March 2024

:: [**Strengthening event-based surveillance systems: a success story from Iraq**](#)

6 March 2024

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

7 March 2024

[**WHO's Operational Update on Health Emergencies - February 2024**](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 109, pp. 105–114 8 March 2024

<https://iris.who.int/bitstream/handle/10665/376217/WER9910-eng-fre.pdf>

:: Progress towards elimination of rubella and congenital rubella syndrome – worldwide, 2012–2022

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

8 March 2024

[Summary of WHO symposium on meeting the global needs for oxygen and respiratory care](#)

7 March 2024

[Medication without harm: Policy brief](#)

Overview

Patient harm due to unsafe care is a leading cause of death and disability worldwide, and most of such harm is avoidable. Harm due to medicines and therapeutic options accounted for nearly 50% of the overall preventable harm in medical care. The pooled prevalence of preventable medication-related harm was 5% (1 in 20 patients) and one fourth of the harm was severe or potentially life-threatening. The prevalence of preventable medication-related harm was nearly double, 7% (1 on 25 patients) in low and middle-income countries (LMICs) compared to 4% (1 in 14 patients) in high-income countries.

This policy brief defines key concepts of medication safety and presents current evidence on the scale of the problem and the urgency of the situation. Medication errors occur throughout the medication use process; however, many recent studies indicate that most errors occur during prescribing and monitoring stages. Evidence of medication-related harm in several contexts and environments are discussed.

7 March 2024

[Global burden of preventable medication-related harm in health care: a systematic review](#)

Overview

Medication-related harm is considered preventable if it occurs as a result of an identifiable, modifiable cause and its recurrence can be avoided by appropriate adaptation to a process or adherence to guidelines. Understanding the prevalence, nature and severity of preventable medication-related harm is critical for setting targets for clinically relevant, implementable improvements in patient safety. This report presents an updated systematic review and meta-analysis of studies of the prevalence, nature and severity of preventable medication-related harm in the international literature including in low- and middle-income countries (LMICs). The main target audience is policy makers, health care leaders, researchers and academics, practicing clinicians and advocacy groups on medication safety.

5 March 2024

[Technical Brief: Enhancing Readiness for Omicron \(B.1.1.529\) in the WHO South-East Asia Region Interim...](#)

4 March 2024

[Refugee and migrant health system review: challenges and opportunities for long-term health system strengthening in Czechia...](#)

4 March 2024

[Making older persons visible in the sustainable development goals' monitoring framework and indicators](#)

3 March 2024

[Strategy for optimizing national routine health information systems: strengthening routine health information...](#)

3 March 2024

[WHO Global Benchmarking Tool \(GBT\) for evaluation of national regulatory system of medical products:...](#)

Overview

This manual is intended to provide clear operational guidance on the benchmarking of regulatory systems for medical products and the development of institutional development plans (IDPs) to address areas for improvement.

The manual is integral to the World Health Organization's structured and evidence-based approach to regulatory systems strengthening (RSS), mandated by World Health Assembly resolution WHA 67.20. The manual serves to ensure a proper understanding of the Global Benchmarking Tool (GBT); the processes and principles that govern its use; the expectations of individuals and institutions involved; and the information management systems that underpin the collection, analysis and management of data and the generation of knowledge...

.....
.....

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No new digest content identified.

CDC/ACIP [U.S.] [to 09 Mar 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

[**CDC study shows effectiveness of RSV immunization for infants**](#)

March 7, 2024

New data released today in CDC's MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).

ACIP Meetings

Next ACIP Meeting
June 26-28

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

March 7, 2024 / No. 9

[PDF of this issue](#)

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee \(PRAC\) 4-7 March 2024](#)

PRAC finds no link between mRNA COVID-19 vaccines and postmenopausal bleeding
8 March 2024

[DARWIN EU® continues expanding its capacity to deliver real-world data studies](#)

The Data Analysis and Real World Interrogation Network DARWIN EU seeks ten new data partners in 2024.

6 March 2024

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[STI cases on the rise across Europe](#)

News story - 7 Mar 2024

.....
.....

Africa CDC [to 09 Mar 2024]

<http://www.africacdc.org/>

Press Releases, Statements [Selected]

No new digest content identified.

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 09 Mar 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 09 Mar 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

Weekly Reports: Current Volume (6)

2024-03-08 / No. 10 BIG DATA FOR WOMEN'S HEALTH ISSUE

[View PDF of this issue](#)

- [Foreword: Using Healthcare Big Data Analytics to Improve Women's Health: Benefits, Challenges, and Perspectives](#)
- [Preplanned Studies: Prevalence of Reproductive Tract Infections and Association with Human Papillomavirus Infection Among Reproductive-Age Women — Six Tertiary Hospitals, China, June 2021–December 2022](#)
- [Vital Surveillances: Incidence and Mortality of Cancers in Female Genital Organs — China, 2022](#)

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 09 Mar 2024]

<https://alleninstitute.org/news-press/>

News

[Allen Institute joins the Weill Neurohub](#)

03.06.2024

Newest member of the research network will bring large-scale data collection and cutting-edge analysis to help discover new therapies for disease.

BMGF - Gates Foundation [to 09 Mar 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

Press release Mar 08, 2024

[WTA Foundation and Gates Foundation launch new campaign—Women Change the Game—to urge action on women's health and nutrition](#)

Campaign includes the groundbreaking WTA Foundation Global Women's Health Fund, which aims to help at least 1 million women in its first year with an inaugural donation from WTA Tour title sponsor Hologic

ST. PETERSBURG, FLA. and SEATTLE (March 8, 2024)—Today, on International Women’s Day, the WTA Foundation and the Bill & Melinda Gates Foundation unveiled Women Change the Game, a new campaign uniting the power of women’s tennis and philanthropy to elevate women’s health and nutrition as a global priority. A key component of the campaign is the first-of-its-kind WTA Foundation Global Women’s Health Fund. With an inaugural donation from WTA Tour title sponsor Hologic, in its first year, the Fund will focus on a key aspect of preventive care: It aims to support at least one million women with prenatal vitamins in low- and middle-income countries where access to adequate nutrition for maternal health is limited...

Press release Mar 05, 2024

[Wave of New Commitments Marks Historic Step Towards the Elimination of Cervical Cancer](#)

...The nearly US\$600 million in new funding includes US\$180 million from the Bill & Melinda Gates Foundation, US\$10 million from UNICEF, and US\$400 million from the World Bank. A full list and description of commitments can be found [here](#) and will be updated throughout the forum.

Bill & Melinda Gates Medical Research Institute [to 09 Mar 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X [to 09 Mar 2024]

<https://carb-x.org/>

News

03.06.2024 |

[CARB-X launches new funding round to fill major R&D gaps in global pipeline](#)

CARB-X seeks preventatives of invasive disease, diagnostics for neonatal sepsis and novel sample types for lower respiratory tract infections, and therapeutics for infections caused by gram-negative pathogens.

03.05.2024 |

[CARB-X funds 100th project targeting antibiotic resistance](#)

CARB-X awards US\$1.06 million to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), our 100th project to address antibiotic resistance.

CEPI – Coalition for Epidemic Preparedness Innovations [to 09 Mar 2024]

<http://cepi.net/>

Latest News

News

[New research to investigate next generation ‘trans-amplifying’ mRNA vaccines](#)

- Promising technology to be tested in preclinical studies funded by CEPI
- The innovation could enable up to 100 times less antigen-encoded mRNA per vaccine dose and for parts of the vaccine to be made ahead of an outbreak
- Some lifesaving COVID-19 vaccines use mRNA, and the innovation could be key to more rapidly responding to future threats

07 March 2024, OSLO, Norway and BOSTON, MA – Scientists in the US are set to test a new vaccine approach that could overcome some of the challenges associated with the latest mRNA vaccine designs and more rapidly create pandemic-busting vaccines in as little as 100 days.

With up to US \$1 million in funding from CEPI, researchers at Amplitude Therapeutics will perform preclinical studies that assess whether their trans-amplifying mRNA vaccine approach could provide a simplified alternative to the self-amplifying mRNA vaccine technique being used today.

Alongside conventional* mRNA vaccines—the technology behind multiple safe and effective COVID-19 vaccines that have helped to save millions of lives—self-amplifying mRNA designs have become more prominent in recent years, with the first-ever licensure of a self-amplifying mRNA COVID-19 vaccine in Japan in November 2023.

Rather than the traditional vaccine approach of injecting an antigen (a substance that induces an immune response) directly into the recipient, mRNA platforms use the body's own cell machinery to make the antigen. Self-amplifying mRNA vaccines are even more specialised as they contain genetic instructions that not only encode for the antigen but also replicase, an enzyme that serves as a built-in photocopier teaching the body how to make more mRNA...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 09 Mar 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 09 Mar 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 09 Mar 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 09 Mar 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

08 March 2024

[International Women's Day 2024: Investing in women to accelerate progress](#)

Emory Vaccine Center [to 09 Mar 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 09 Mar 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 09 Mar 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

No new digest content identified.

Fondation Merieux [to 09 Mar 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 09 Mar 2024]

<https://www.gavi.org/>

News Releases

8 March 2024

[Vaccine Alliance outlines path to improve HPV vaccine market](#)

- A new Gavi market shaping roadmap for HPV vaccines showcases how partners, manufacturers and countries must work together to secure a sustainable supply over the next decade.
- The action plan outlines how this can be achieved by improving the predictability of demand, a competitive supplier base, and closely monitoring and responding to countries' needs.
- Aurélia Nguyen, Chief Programme Officer at Gavi: "Lower-income countries have missed out on HPV vaccines for far too long. To ensure we reach our goal of protecting 86 million girls by 2025, it's vital that our current supply of doses is managed carefully, and we have donor and manufacturer support to go further and protect more girls."

6 March 2024

[Wave of new commitments marks historic step towards the elimination of cervical cancer](#)

New country, policy and program commitments, plus nearly US\$600 million in new funding, at first-ever global forum offer a chance to save hundreds of thousands of lives by 2030.

Cartagena de Indias, Colombia, 5 March 2024 – Governments, donors, multilateral institutions, and partners today announced major new policy, programmatic and financial commitments, including nearly US\$600 million in new funding, to eliminate cervical cancer. If these ambitions to expand vaccine coverage and strengthen screening and treatment programs are fully realized, the world could eliminate a cancer for the first time.

These commitments were made at the first-ever Global Cervical Cancer Elimination Forum: Advancing the Call to Action in Cartagena de Indias, Colombia, to catalyze national and global momentum to end this preventable disease...

GE2P2 Global Foundation [to 09 Mar 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 07 March 2024 – Issue 14](#)

GHIT Fund [to 09 Mar 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 09 Mar 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 09 Mar 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 09 Mar 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 09 Mar 2024]

<https://www.hhmi.org/news>

Press Room

[A Mission to Keep Veterans in STEM](#)

HHMI Professor Marla Geha launched a first-of-its-kind program at Yale that provides military veterans hands-on research experience in their undergraduate years. The program will welcome a new cohort this summer.

March 04, 2024

Human Immunome Project [nee Human Vaccines Project] [to 09 Mar 2024]

<http://www.humanvaccinesproject.org/>

News

Press Releases

[Announcing 2023 Michelson Prize Laureates](#)

Three early career scientists, Dr. Siyuan Ding, Dr. Claire Otero, and Dr. Dennis Schaefer-Babajew, to receive \$150,000 Grants for immunology and vaccine research.

IAVI [to 09 Mar 2024]

<https://www.iavi.org/>

News, Features

Features

[IAVI and partners kick-start CELEBRATE study to explore acceptability and feasibility of bnAbs for infant HIV prevention](#)

March 5, 2024

Study focuses on socio-behavioral research to enhance understanding of preferences and factors influencing bnAb adoption for infant indication.

INSERM [to 09 Mar 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 09 Mar 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 09 Mar 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[A statement on Gaza and Israel from the president of the ICRC](#)

This brutal war has ruptured any sense of a shared humanity.

09-03-2024 | Article

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 09 Mar 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 09 Mar 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 09 Mar 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 09 Mar 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 09 Mar 2024]

<http://www.ivi.int/>

IVI News & Announcements

[**IVI participates as local coordinator in EID Conference & International Symposium for IDRIC**](#)

Johns Hopkins Center for Health Security [to 09 Mar 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 09 Mar 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Democratic Republic of Congo

[**MSF calls for protection of patients, medical facilities and civilians following Drodro hospital attack**](#)

Press Release 8 Mar 2024

Panama

[**MSF forced to suspend medical care for people on the move in Panama**](#)

Press Release 7 Mar 2024

Nigeria

[An arduous journey for pregnant women to access healthcare in northwest Nigeria](#)

Project Update 7 Mar 2024

Haiti

[Scaling up medical activities amid chaos in Port-au-Prince](#)

Press Release 6 Mar 2024

National Academy of Medicine - USA [to 09 Mar 2024]

<https://nam.edu/programs/>

News [Selected]

[NAM Recognizes International Women's Day](#)

March 8, 2024

National Academy of Sciences - USA [to 09 Mar 2024]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 09 Mar 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

June 13-14, 2024

NIH [to 09 Mar 2024]

<http://www.nih.gov/>

March 6, 2024

[Children surpass a year of HIV remission after treatment pause](#)

NIH-funded trial shows promising outcomes with treatment started promptly after birth.

March 5, 2024

[Vaginal ring and oral pre-exposure prophylaxis found safe for HIV prevention throughout pregnancy](#)

Multi-country findings provide evidence on HIV prevention for a priority population.

PATH [to 09 Mar 2024]

<https://www.path.org/media-center/>

Newsroom

[Join PATH at the East Africa Regional Early Childhood Development Conference in Dar es Salaam, Tanzania](#)

March 8, 2024 by PATH

Sabin Vaccine Institute [to 09 Mar 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 09 Mar 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

6 March 2024

[On International Women's Day, UNAIDS calls for protecting women's rights to protect their health](#)

8 March 2024

[Asia Pacific women living with HIV build their power through Feminist School](#)

7 March 2024

[Community leadership driving progress to eliminate mother-to-child HIV transmission in Indonesia](#)

UNICEF [to 09 Mar 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Statement 08 March 2024

[Statement by UNICEF Executive Director Catherine Russell on children in Sudan at risk of famine](#)

NEW YORK, 8 March 2024 – “The brutal war in Sudan is pushing the country toward famine and a catastrophic loss of life, especially among children. In what is now the world’s largest child displacement crisis, severe malnutrition among young children is intensifying beyond the worst projections, and there are outbreaks of cholera, measles and...

Press release 05 March 2024

[Wave of new commitments marks historic step towards the elimination of cervical cancer](#)

CARTAGENA DE INDIAS, COLOMBIA, 5 March 2024 – Governments, donors, multilateral institutions, and partners today announced major new policy, programmatic and financial commitments, including nearly US\$600 million in new funding, to eliminate cervical cancer. If these ambitions to expand vaccine coverage and strengthen screening and treatment...

Unitaid [to 09 Mar 2024]

<https://unitaid.org/>

Featured News

07 March 2024

[Innovation critical to achieving the commitments to reduce deaths from malaria made at Ministerial Meeting this week](#)

06 March 2024

[In advance of International Women's Day, Unitaid Board Chair calls for urgent action to advance access to cervical cancer prevention for women in resource-limited settings](#)

Vaccine Equity Cooperative [nee Initiative] [to 09 Mar 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 09 Mar 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 09 Mar 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 09 Mar 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 09 Mar 2024]

<https://wellcome.org/>

News, Opinion, Reports

No new digest content identified.

The Wistar Institute [to 09 Mar 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 09 Mar 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 09 Mar 2024]

<https://www.wfpha.org/>

Blog

No new digest content identified.

World Medical Association [WMA] [to 09 Mar 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 09 Mar 2024]

<https://www.oie.int/en/>
Press Releases, Statements
No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 09 Mar 2024]

<https://alliancerm.org/press-releases/>
Selected Press Releases
No new digest content identified.

BIO [to 09 Mar 2024]

<https://www.bio.org/press-releases>
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 09 Mar 2024]

<http://www.dcvmn.org/>
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 09 Mar 2024]

<https://internationalbiotech.org/news/>
News
No new digest content identified.

IFPMA [to 09 Mar 2024]

<https://ifpma.org/>
News

Statement 1 Mar 2024

[Resumed session of the 7th Meeting of the Working Group on Amendments to the International Health Regulations \(2005\)](#)

On 8 March 2024, IFPMA delivered a statement at the resumed session of the 7th Meeting of the Working Group on Amendments to the International Health Regulations in Geneva, where the focus of discussions was on equity.

Amendments proposed to the International Health Regulations (IHR) (2005) must support equitable access and focus more on the equitable rollout of medical countermeasures (MCMs).

Achieving equitable access to MCMs requires a comprehensive solution and should not be based on linking access to pathogen samples and sequence data to benefit-sharing obligations. The innovative pharmaceutical industry is willing to make commitments to support equitable access to vaccines, therapeutics, and diagnostics, but those should not be conditional on its ability to access pathogens quickly and indiscriminately.

Looking at the inequitable rollout of MCMs during COVID-19, **our willingness to set aside a proportion of real time production is highly relevant. Our companies are committed to doing more and better on equitable roll-out as mentioned the [Berlin Declaration](#).**

Companies are prepared to commit to pre- and during- pandemic measures, including improving surveillance; research on pathogens of pandemic potential; voluntary licensing and technology

transfer based on mutually agreed terms to improve geographic diversification of manufacturing; real-time allocation of part of production; and equity-based tiered pricing.

Companies are also engaged in activities to support health system preparedness, whether by building clinical trial and regulatory capacity and harmonization, health care worker and community health worker trainings, or the continual investment needed to establish and maintain new technologies and platforms.

We reaffirm our full commitment to constructively contribute. We stand ready to cooperate and collaborate closely with Member States and other stakeholders to facilitate convergence toward successful outcomes in May.

International Alliance of Patients' Organizations – IAPO [to 09 Mar 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 09 Mar 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest announcements identified.*

Bharat Biotech

Press Releases - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News - *No new digest announcements identified*

BioNTech

Press Releases - *No new digest announcements identified*

Boehringer

Press Releases - *No new digest announcements identified.*

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals - China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media - No new digest announcements identified

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified

Merck

News releases

[Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24](#)

March 6, 2024 10:25 am ET

- Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People with HIV
- Novel Investigational Combination Regimen has the Potential to be the First Oral Weekly HIV Treatment, Helping to Address Unmet Needs

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified [English translation function not operating]

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases

[SK bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline](#)

2024.03.07

...SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company broke ground on a major expansion of its vaccine manufacturing plant, L HOUSE, located in Andong, Gyeongsangbuk-do, South Korea. The groundbreaking ceremony was attended by Cheol-woo Lee, Governor Gyeongsangbuk-do, GiChang Kwon, Mayor Andong City, Pascal Robin, General Manager and Representative Director of Vaccines at Sanofi Korea, and Jaeyong Ahn, CEO of SK bioscience, on March 6, 2024.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....

.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....

.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 3: E195-273 Mar 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Psychiatric Inpatient Environmental Architecture

Inpatient psychiatric units designed to reduce patients' risk of harm to self or others can compromise patients' comfort. Some environmental modifications prioritize safety by limiting patients' access to personal items. This set of clinical phenomena is not ethically neutral and should prompt us to carefully consider when and how patients' experiences of their care environments undermine therapeutic goals of their hospitalizations. This theme issue investigates which criteria we should use to assess and evaluate patients' risk of harm to self or others and which values we should rely upon to guide which iatrogenic harm risks we accept as products or byproducts of clinical and organizational environmental designs.

[Reviewed earlier]

American Journal of Human Genetics

Feb 01, 2024 Volume 111 Issue 2p211-402

<https://www.cell.com/ajhg/current>

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Human genetic variation influences susceptibility to infectious disease. Antibodies, stable biological markers of the response to infection, can be measured and leveraged to understand disease exposure, chronic infection state, and risk. Measured antibody titers in combination with genome-wide genotyping data can be used to identify common variants that influence both susceptibility and response to infectious disease. In this issue, Chong et al. perform a genome-wide association study of quantitative antibody responses to 45 antigens on the 9,611 individuals in the UK Biobank with both serology and imputed genetic data.

American Journal of Infection Control

March 2024 Volume 52 Issue 3 p261-380

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

March 2024 Volume 66 Issue 3 p389-572

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

March 2024 114(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 2 (Feb 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/2/tpmd.110.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

February 2024 Volume 177, Issue 2

<https://www.acpjournals.org/toc/aim/current>

Original Research

[Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States - A Cost-Effectiveness Analysis](#)

Anirban Basu, PhD, ... et al.

Pages:155–164

The U.S. Food and Drug Administration recently approved 2 genetic therapies for sickle cell disease. Both therapies increase the production of nonsickling red blood cells, either fetal hemoglobin or a gene therapy–derived hemoglobin similar to hemoglobin A. In addition, both therapies require collection of a patient’s stem cells, modification of the cells in the laboratory, high-dose chemotherapy to remove existing bone marrow cells, and a single-dose infusion of the patient’s modified stem cells. This article uses 2 different cost-effectiveness models to estimate whether these therapies provide enough value to justify their high costs.

[Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents](#) FREE

Qiong Wu, PhD, ... et al.

Pages:165–176

Using electronic health record data from a national collaboration of pediatric health systems, this study examined the effectiveness of BNT162b2 vaccines for preventing COVID-19 infections and severe disease among previously uninfected children and adolescents. It found moderate effectiveness of the vaccine against the SARS-CoV-2 Omicron variant and high effectiveness against the Delta variant.

[Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting](#)

Ousseny Zerbo, PhD, ... et al.

Pages:189–195

A previous pivotal clinical trial found that a 2-dose series of recombinant zoster vaccine (RZV) had high effectiveness against herpes zoster. This prospective cohort study evaluated the real-world effectiveness of RZV against herpes zoster.

Clinical Guidelines

[Recommended Adult Immunization Schedule, United States, 2024*](#)

Neil Murthy, MD, MPH, MSJ, A. Patricia Wodi, MD, Veronica V. McNally, JD, Matthew F. Daley, MD, and Sybil Cineas, MD, on behalf of the Advisory Committee on Immunization Practices

Pages:221–237

Artificial Intelligence – An International Journal

Volume 328 March 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/328/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 09 Mar 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 09 Mar 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 09 Mar 2024)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 09 Mar 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 09 Mar 2024)

[Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination](#)

The emergence of new SARS-CoV-2 variants and the waning of immunity raise concerns about vaccine effectiveness and protection against COVID-19. While antibody response has been shown to correlate with the risk...

Authors: Carla Martín Pérez, Ruth Aguilar, Alfons Jiménez, Gemma Salmerón, Mar Canyelles, Rocío Rubio, Marta Vidal, Inocencia Cuamba, Diana Barrios, Natalia Díaz, Rebeca Santano, Pau Serra, Pere Santamaria, Luis Izquierdo, Antoni Trilla, Anna Vilella...

Citation: BMC Medicine 2024 22:103

Content type: Research article Published on: 8 March 2024

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 09 Mar 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 09 Mar 2024)

[Pneumococcal vaccine uptake among high-risk adults and children in Italy: results from the OBVIOUS project survey](#)

Streptococcus pneumoniae infections, including Invasive Pneumococcal Diseases (IPDs), pose a substantial public health challenge, causing significant morbidity and mortality, especially among children and older ...

Authors: Zeno Di Valerio, Giusy La Fauci, Francesca Scognamiglio, Aurelia Salussolia, Marco Montalti, Angelo Capodici, Maria Pia Fantini, Anna Odone, Claudio Costantino, Giorgia Soldà, Heidi J. Larson, Julie Leask, Jacopo Lenzi and Davide Gori

Citation: BMC Public Health 2024 24:736

Content type: Research Published on: 7 March 2024

[Associations of geographic-based socioeconomic factors and HPV vaccination among male and female children in five US states](#)

We assessed whether five geographic-based socioeconomic factors (medically underserved area (MUA); healthcare provider shortage area (HPSA); persistent poverty; persistent child poverty; and social vulnerabili...

Authors: Serena Xiong, Sarah Humble, Alan Barnette, Heather Brandt, Vetta Thompson, Lisa M. Klesges and Michelle I. Silver

Citation: BMC Public Health 2024 24:702

Content type: Research Published on: 5 March 2024

[Correlation of geopolitics, education, democracy with COVID-19 vaccination rate](#)

Vaccine hesitancy is an ongoing problem and determining the factors that increase the vaccination rate in various countries of the world might be useful for further implementation of efficient public health po...

Authors: Konstantine Chakhunashvili, Davit G. Chakhunashvili, Eka Kvirkvelia, Tornike Toria, Liza Basilaia and Tsira Gorjomeladze

Citation: BMC Public Health 2024 24:694

Content type: Research Published on: 4 March 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 09 Mar 2024)
[No new digest content identified]

BMJ Evidence-Based Medicine

February 2024 - Volume 29 - 1
<https://ebm.bmj.com/content/29/1>
[Reviewed earlier]

BMJ Global Health

March 2024 - Volume 9 - 3
<https://gh.bmj.com/content/9/3>
Analysis

[Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group](#) (7 March, 2024)

Rebecca E Chandler, Madhava Ram Balakrishnan, Daniel Brasseur, Philip Bryan, Emmanuelle Espie, Katharina Hartmann, Corinne Jouquelet-Royer, James Milligan, Linda Nesbitt, Shanthi Pal, Alexander Precioso, Paulo Takey, Robert T Chen

Commentary

[Public health emergencies in war and armed conflicts in Africa: What is expected from the global health community?](#) (8 March, 2024)

Jean Kaseya, Nebiyu Dereje, Tajudeen Raji, Alain Ngashi Ngongo, Mosoka Papa Fallah, Nicaise Ndembu

Original research

[The impact of policy and policy communication on COVID-19 vaccination inequalities among Venezuelan refugees and migrants in Colombia: a comparative cross-sectional interrupted time-series analysis](#) (7 March, 2024)

Wilson Gomez, Julián A Fernández-Niño, José Rafael Guillén, Megan Stevenson, Jennifer Ortíz, Miguel Ángel Barriga Talero, Jhon Jairo López, Ricardo Luque Núñez, Paul Spiegel, Kathleen R Page, Jhon Fredy Ramirez Correa, Damary Martínez Porras, Andrea L Wirtz

[Maternal and perinatal health research during emerging and ongoing epidemic threats: a landscape analysis and expert consultation](#) (7 March, 2024)

Mercedes Bonet, Magdalena Babinska, Pierre Buekens, Shivaprasad S Goudar, Beate Kampmann, Marian Knight, Dana Meaney-Delman, Smaragda Lamprianou, Flor Muñoz Rivas, Andy Stergachis, Cristiana M Toscano, Joycelyn Bhatia, Sarah Chamberlain, Usman Chaudhry, Jacqueline Mills, Emily Serazin, Hannah Short, Asher Steene, Michael Wahlen, Olufemi T Oladapo

Abstract

Introduction

Pregnant women and their offspring are often at increased direct and indirect risks of adverse outcomes during epidemics and pandemics. A coordinated research response is paramount to ensure that this group is offered at least the same level of disease prevention, diagnosis, and care as the general population. We conducted a landscape analysis and held expert consultations to identify research efforts relevant to pregnant women affected by disease outbreaks, highlight gaps and challenges, and propose solutions to addressing them in a coordinated manner.

Methods

Literature searches were conducted from 1 January 2015 to 22 March 2022 using Web of Science, Google Scholar and PubMed augmented by key informant interviews. Findings were reviewed and

Quid analysis was performed to identify clusters and connectors across research networks followed by two expert consultations. These formed the basis for the development of an operational framework for maternal and perinatal research during epidemics.

Results

Ninety-four relevant research efforts were identified. Although well suited to generating epidemiological data, the entire infrastructure to support a robust research response remains insufficient, particularly for use of medical products in pregnancy. Limitations in global governance, coordination, funding and data-gathering systems have slowed down research responses.

Conclusion

Leveraging current research efforts while engaging multinational and regional networks may be the most effective way to scale up maternal and perinatal research preparedness and response. The findings of this landscape analysis and proposed operational framework will pave the way for developing a roadmap to guide coordination efforts, facilitate collaboration and ultimately promote rapid access to countermeasures and clinical care for pregnant women and their offspring in future epidemics.

Bulletin of the Atomic Scientists

March 2024

<https://thebulletin.org/magazine/2024-03/>

[New issue; No digest content identified]

Bulletin of the World Health Organization

Volume 102(3); 2024 Mar 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/456622/>

[Reviewed earlier]

Cell

Feb 29, 2024 Volume 187 Issue 5 p1017-1314

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 3 Pages: 375-626 March 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Subcutaneous Biologics: Clinical Pharmacology and Drug Development

[Reviewed earlier]

Clinical Therapeutics

February 2024 Volume 46 Issue 2 p85-184

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 1, February 2024

<https://journals.sagepub.com/toc/ctja/21/1>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 09 Mar 2024]

[Community-based surveillance programme evaluation using the platform Nyss implemented by the Somali Red Crescent Society—a mixed methods approach](#)

Authors: Julia Jung, Tine Mejdell Larsen, Abdifatah Hussein Beledi, Emi Takahashi, Abdirahman Omer Ahmed, Jenny Reid and Ida Anine Kongelf

Citation: Conflict and Health 2024 18:20

Content type: Research Published on: 6 March 2024

Background

Somali Red Crescent Society (SRCS), supported by Norwegian Red Cross, has implemented community-based surveillance (CBS) in Somaliland. This methodology aims to reduce the high risk of epidemics by strengthening early warning and response from and at community level, particularly where there is a weak public health surveillance system. CBS is implemented through SRCS community volunteers, who report signals from the community via SMS to the software platform Nyss. This paper presents key findings from the CBS programme evaluation.

Contemporary Clinical Trials

Volume 138 March 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 7, Issue 1 / February 2024

<https://www.liebertpub.com/toc/crispr/7/1>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 2 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2024 - Volume 37 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 09 Mar 2024]

PROTOCOL

Open Access

[The PhenX Toolkit: Recommended Measurement Protocols for Social Determinants of Health Research](#)

[Cataia L. Ives](#), [Michelle C. Krzyzanowski](#), [Vanessa J. Marshall](#), [Keith Norris](#), [Myles Cockburn](#), [Keisha Bentley-Edwards](#), [Dinushika Mohottige](#), [Keshia M. Pollack Porter](#) ... [See all authors](#)

First published: 05 March 2024

<https://doi.org/10.1002/cpz1.977>

Abstract

Health disparities are driven by unequal conditions in the environments in which people are born, live, learn, work, play, worship, and age, commonly termed the Social Determinants of Health (SDoH). The availability of recommended measurement protocols for SDoH will enable investigators to consistently collect data for SDoH constructs. The PhenX (consensus measures for Phenotypes and eXposures) Toolkit is a web-based catalog of recommended measurement protocols for use in research studies with human participants. Using standard protocols from the PhenX Toolkit makes it easier to compare and combine studies, potentially increasing the impact of individual studies, and aids in comparability across literature. In 2018, the National Institute on Minority Health and Health Disparities provided support for an initial expert Working Group to identify and recommend established SDoH protocols for inclusion in the PhenX Toolkit. In 2022, a second expert Working Group was convened to build on the work of the first SDoH Working Group and address gaps in the SDoH Toolkit Collections. The SDoH Collections consist of a Core Collection and Individual and Structural Specialty Collections. This article describes a Basic Protocol for using the PhenX Toolkit to select and implement SDoH measurement protocols for use in research studies.

Developing World Bioethics

Volume 24, Issue 1 Pages: 1-48 March 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

Access to Essential Medicines for Global Health and the Human Right to Health

[Reviewed earlier]

Development in Practice

Volume 34, Issue 1, 2024

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/1>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 2 13 February 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 2—February 2024

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 46 March 2024

<https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C>

[New issue; No digest content identified]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 2 Pages: 1-35 March–April 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Indigenous data sovereignty :: Returning clinically relevant results

Articles Open Access

[Navigating University Openness in Research Policy Inconsistent with Indigenous Data Sovereignty: A Case Analysis](#)

Molly Wick, Deanna Erickson, Joel Hoffman, Lucinda Johnson, Ted Angradi

Pages: 2-15

First Published: 06 March 2024

[Returning Clinically Relevant Research Results to Participants: Guidelines for Investigators and the IRB](#)

Amy Waltz, Bethany Johnson, Peter H. Schwartz

Pages: 22-29

First Published: 06 March 2024

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2023 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 3 March 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/3>

Research article Open access

[**Secondary \(additional\) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure**](#)

Joshua Nolan, James Buchanan, John Taylor, Joao Almeida, ... Elizabeth Ormondroyd

Article 101051

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 09 Mar 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 1 February 28, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 09 Mar 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 09 Mar 2024]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 1, January 2024

<https://academic.oup.com/heapol/issue/39/1>

Commentary

[Innovative health financing mechanisms: the case of Africa's unified approach to vaccine acquisition](#)

Chiamaka P Ojiako

Health Policy and Planning, Volume 39, Issue 1, January 2024, Pages 84–86,

<https://doi.org/10.1093/heapol/czad109>

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 09 Mar 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 3-4 / February 2024

<https://www.liebertpub.com/toc/hum/35/3-4>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Feb 13, 2024 Volume 57 Issue 2 p193-400

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 09 Mar 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 09 Mar 2024]

[No new digest content identified]

International Health

Volume 16, Issue 2, March 2024

<https://academic.oup.com/inthealth/issue/16/2>

[New issue; No digest content identified]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 3 (2024): March 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>

[Reviewed earlier]

International Journal of Epidemiology

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

Table of contents

[Reviewed earlier]

JAMA

March 5, 2024, Vol 331, No. 9, Pages 721-808

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

March 2024, Vol 5, No. 3

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

March 2024, Vol 178, No. 3, Pages 211-322

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Viewpoint

Artificial Intelligence and Pediatric Care

[An Overarching Framework for the Ethics of Artificial Intelligence in Pediatrics](#)

Bryan A. Sisk, MD, MSCI; Alison L. Antes, PhD; James M. DuBois, PhD, DSc

Artificial intelligence (AI) is rapidly evolving and AI-powered technologies will likely transform pediatric health care. AI can support accurate and efficient interpretation of chest radiography and retinal images,¹ and will likely improve diagnosis, risk prediction, and treatment selection in the

future. Rapid advances in the abilities of chatbots driven by large language models (LLMs), such as ChatGPT, could democratize medical knowledge and inform treatment decisions.

JBI Evidence Synthesis

February 2024 - Volume 22 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

March 2024 Volume 74 Issue 3 p395-628

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 167 March 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/167/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

February 2024 - Volume 78 - 2

<https://jech.bmj.com/content/78/2>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 1 Pages: 1-772 January 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

March 2024 - Volume 50 - 3

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 266 March 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/266/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 1, March 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-1>

[New issue; No digest content identified]

Journal of the Royal Society – Interface

March 2024 Volume 21 Issue 212

<https://royalsocietypublishing.org/toc/rsif/current>

Research articles

[Reconciling the efficacy and effectiveness of masking on epidemic outcomes](#)

[Wan Yang](#) and [Jeffrey Shaman](#)

Published:06 March 2024

<https://doi.org/10.1098/rsif.2023.0666>

Abstract

During the COVID-19 pandemic, mask wearing in public settings has been a key control measure. However, the reported effectiveness of masking has been much lower than laboratory measures of efficacy, leading to doubts on the utility of masking. Here, we develop an agent-based model that comprehensively accounts for individual masking behaviours and infectious disease dynamics, and test the impact of masking on epidemic outcomes. Using realistic inputs of mask efficacy and contact data at the individual level, the model reproduces the lower effectiveness as reported in randomized controlled trials. Model results demonstrate that transmission within households, where masks are rarely used, can substantially lower effectiveness, and reveal the interaction of nonlinear epidemic dynamics, control measures and potential measurement biases. Overall, model results show that, at the individual level, consistent masking can reduce the risk of first infection and, over time, reduce the frequency of repeated infection. At the population level, masking can provide direct protection to mask wearers, as well as indirect protection to non-wearers, collectively reducing

epidemic intensity. These findings suggest it is prudent for individuals to use masks during an epidemic, and for policymakers to recognize the less-than-ideal effectiveness of masking when devising public health interventions.

Journal of Travel Medicine

Volume 31, Issue 2, March 2024

<https://academic.oup.com/jtm/issue>

Perspective

[Rationale for Japanese encephalitis vaccination in short-term travellers to endemic areas](#)

Sakarn Charoensakulchai and others

Journal of Travel Medicine, Volume 31, Issue 2, March 2024, taae003,

<https://doi.org/10.1093/jtm/taae003>

Although the Japanese encephalitis (JE) vaccine is typically strongly recommended for long-term high-risk travellers, some cases of JE infections have been reported amongst short-term travellers with seemingly low risk. This article underscores the advantages and reasoning behind JE vaccination for this particular group of travellers.

Research Letter

[Unprecedented dengue outbreak in Taiwan following COVID-19](#)

Nan-Chang Chiu and others

Journal of Travel Medicine, Volume 31, Issue 2, March 2024, taae015,

<https://doi.org/10.1093/jtm/taae015>

Present study reports an unprecedented dengue outbreak in Taiwan post-COVID-19. Interrupted time series analysis reveals a significant surge after easing restrictions, emphasizing the roles of COVID-19 measures, especially travel restrictions, international transportation and climate change in the epidemic. Preventing and controlling dengue remain substantial challenges in the post-COVID-19 era.

Journal of Virology

Volume 98 • Number 2 • February 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Mar 09, 2024 Volume 403 Number 10430 p877-996

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

The Lancet Child & Adolescent Health

Mar 2024 Volume 8 Number 3 p175-244, e2-e5

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Mar 2024 Volume 6 Number 3 e145-e229

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Mar 2024 Volume 12 Number 3 e341-e529

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Mar 2024 Volume 24 Number 3 p217-328, e137-e206

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Mar 2024 Volume 9 Number 3 e147-e206

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Mar 2024 Volume 12 Number 3 p181-254, e7-e12

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 2, February 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 101, Issue 4 Pages: 999-1374 December 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Mar 06, 2024 Volume 32 Issue 3 p563-856

<https://www.cell.com/molecular-therapy/current>

[New issue; No digest content identified]

Nature

Volume 627 Issue 8002, 7 March 2024

<https://www.nature.com/nature/volumes/626/issues/8002>

Editorial 06 Mar 2024

[Nature publishes too few papers from women researchers — that must change](#)

This journal will double down on efforts to diversify the pool of corresponding authors and referees.

Perspective 06 Mar 2024

[Artificial intelligence and illusions of understanding in scientific research](#)

Lisa Messeri, M. J. Crockett

Abstract

Scientists are enthusiastically imagining ways in which artificial intelligence (AI) tools might improve research. Why are AI tools so attractive and what are the risks of implementing them across the research pipeline? Here we develop a taxonomy of scientists' visions for AI, observing that their appeal comes from promises to improve productivity and objectivity by overcoming human shortcomings. But proposed AI solutions can also exploit our cognitive limitations, making us vulnerable to illusions of understanding in which we believe we understand more about the world than we actually do. Such illusions obscure the scientific community's ability to see the formation of scientific monocultures, in which some types of methods, questions and viewpoints come to dominate alternative approaches, making science less innovative and more vulnerable to errors. The proliferation of AI tools in science risks introducing a phase of scientific enquiry in which we produce more but understand less. By analysing the appeal of these tools, we provide a framework for advancing discussions of responsible knowledge production in the age of AI.

Nature Biotechnology

Volume 42 Issue 2, February 2024

<https://www.nature.com/nbt/volumes/42/issues/2>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 09 Mar 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 2, February 2024

<https://www.nature.com/ng/volumes/56/issues/2>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 2, February 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/2>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 2, February 2024

<https://www.nature.com/nm/volumes/30/issues/2>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 3, March 2024

<https://www.nature.com/nrd/volumes/23/issues/3>

Comment 06 Feb 2024

[The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases](#)

A public–private partnership managed by the FNIH aims to address biological, manufacturing and regulatory challenges to the development of gene therapies for rare diseases.

P. J. Brooks, Timothy M. Miller, Joni L. Rutter

Nature Reviews Genetics

Volume 25 Issue 3, March 2024

<https://www.nature.com/nrg/volumes/25/issues/3>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 3, March 2024

<https://www.nature.com/nri/volumes/24/issues/3>

[New issue; No digest content identified]

New England Journal of Medicine

March 7, 2024 Vol. 390 No. 10

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 09 Mar 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 3 March 2024

<https://publications.aap.org/pediatrics/issue/153/3>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 3 March 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-3>

[A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments](#)

T. Joseph Mattingly II

Current Opinion 12 December 2023 Pages: 253 - 259

Abstract

A value assessment is intended as a tool for evaluating healthcare treatments to gauge value and inform decisions. Economic value assessments typically incorporate a cost-effectiveness analysis, focusing on costs and health outcomes important to payers, missing important information to ensure existing markets optimize resource allocation. Despite frequent calls for more explicit consideration of health equity impacts in value assessments, health economists continue to develop models informed by traditional cost and quality-of-life data that do not capture differences experienced by health disparity populations. This conceptual paper proposes a research framework to enhance data collection and analysis to address these gaps and better quantify the value of a health innovation, and better assess how a new intervention impacts health disparities. The framework comprises three distinct phases that build on one another: (1) contextualization of lived experiences for disadvantaged communities; (2) individual-level quantification of health disparities for cost and quality-of-life measures; and (3) quantifying community-level impacts.

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 09 Mar 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 09 Mar 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 09 Mar 2024)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 09 Mar 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 09 Mar 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 09 Mar 2024]

[**Immunization coverage and its associated factors among children aged 12–23 months in Ethiopia: An umbrella review of systematic review and meta-analysis studies**](#)

Alemu Birara Zemariam, Gebremeskel Kibret Abebe, Mulat Awoke Kassa, Addis Wondemagegn Alamaw, Rediet Woldesenbet Molla, Biruk Beletew Abate, Befekad Deresse Tilahun, Wubet Tazeb Wondie, Rahel Asres Shimelash, Molla Fentanew
Research Article | published 07 Mar 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0299384>

[Systematic review of social determinants of childhood immunisation in low- and middle-income countries and equity impact analysis of childhood vaccination coverage in Nigeria](#)

Sarah V. Williams, Tanimola Akande, Kaja Abbas
Research Article | published 06 Mar 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0297326>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 09 Mar 2024]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

March 5, 2024 vol. 121 no. 10
<https://www.pnas.org/toc/pnas/121/10>
Research Article February 26, 2024
Coronavirus (COVID-19)

[Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform](#)

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron strain has evolved into highly divergent variants with several sub-lineages. These newly emerging variants threaten the efficacy of available COVID-19 vaccines. To mitigate the ...
Soojeong Chang, Kwang-Soo Shin,[...] Chang-Yuil Kang

PNAS Nexus

Volume 3, Issue 2, February 2024
<https://academic.oup.com/pnasnexus/issue/3/2>
[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 1 - February 2024
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 180 March 2024
<https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

13 March 2024 Volume 291 Issue 2018
<https://royalsocietypublishing.org/toc/rspb/current>
[New issue; No digest content identified]

Public Health

Volume 227 Pages e1-e4, 1-298 (February 2024)
<https://www.sciencedirect.com/journal/public-health/vol/227/suppl/C>
[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023
<http://phe.oxfordjournals.org/content/current>
[Reviewed earlier]

Public Health Genomics

2023, Vol. 26, No. 1
<https://karger.com/phg/issue/26/1>
[Reviewed earlier]

Public Health Reports

Volume 139 Issue 1, January/February 2024
<https://journals.sagepub.com/toc/phrg/139/1>
[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 4, March 2024
<https://journals.sagepub.com/toc/QHR/current>
[Reviewed earlier]

Research Ethics

Volume 20 Issue 1, January 2024
<http://journals.sagepub.com/toc/reab/current>
[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>
[Accessed 09 Mar 2024]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>
8 Mar 2024

[PAHO/WHO Collaborating Centers: celebrating the achievement of our common goals](#)

Editorial | English |
8 Mar 2024

[Research priority-setting is an ethics exercise: lessons from the Global Forum on Bioethics in Research for the Region of the Americas*](#)

Letter | English |

8 Mar 2024

[Ranking of immunization programs in Latin America, 2020](#)

Original research | Spanish |

8 Mar 2024

[Public health surveillance and the data, information, knowledge, intelligence and wisdom paradigm](#)

Opinion and analysis | English |

Risk Analysis

Volume 44, Issue 3 Pages: 509-737 March 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 09 Mar 2024]

[Reviewed earlier]

Science

Volume 383| Issue 6687| 8 Mar 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 30, Issue 1 February 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-1>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 737| 6 Mar 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 09 Mar 2024]

[No new digest content identified]

Social Science & Medicine

Volume 343 February 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/343/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 09 Mar 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 1 February 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-1>

[New issue; No digest content identified]

Travel Medicine and Infectious Diseases

Volume 57 January–February 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/57/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 2 Pages: i-iv, 73-160 February 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 6 Pages 1195-1406 (27 February 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/6>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 09 Mar 2024]

Latest Articles [Selected]

Open Access Review

[Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030](#)

by Said A. Al-Busafi and Ahmed Alwassief

Vaccines **2024**, *12*(3), 288;

<https://doi.org/10.3390/vaccines12030288> (registering DOI) - 09 Mar 2024

Abstract

Annually, more than 1.5 million preventable new hepatitis B (HBV) infections continue to occur, with an estimated global burden of 296 million individuals living with chronic hepatitis B infection. This substantial health challenge results in over 820,000 annual deaths being attributed to complications such as liver cirrhosis and hepatocellular carcinoma (HCC). The HBV vaccination remains the

cornerstone of public health policy to prevent chronic hepatitis B and its related complications. It serves as a crucial element in the global effort to eliminate HBV, as established by the World Health Organization (WHO), with an ambitious 90% vaccination target by 2030. However, reports on global birth dose coverage reveal substantial variability, with an overall coverage rate of only 46%. This comprehensive review thoroughly examines global trends in HBV vaccination coverage, investigating the profound impact of vaccination on HBV prevalence and its consequences across diverse populations, including both high-risk and general demographics. Additionally, the review addresses the essential formidable challenges and facilitating factors for achieving WHO's HBV vaccination coverage objectives and elimination strategies in the coming decade and beyond.

Open Access Review

[Understanding Low Vaccine Uptake in the Context of Public Health in High-Income Countries: A Scoping Review](#)

by [Josephine Etowa](#)

Vaccines 2024, 12(3), 269; <https://doi.org/10.3390/vaccines12030269> - 04 Mar 2024

Abstract

Although the COVID-19 pandemic has caused the need for the largest mass vaccination campaign ever undertaken to date, African, Caribbean, and Black (ACB) populations have shown both a disproportionately high degree of negative impacts from the pandemic and the lowest willingness to become [...]

Value in Health

March 2024 Volume 27 Issue 3 p271-382

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

World Development

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 09 Mar 2024]

Selected Research

Study Protocol metrics AWAITING PEER REVIEW

[Development of a core outcome set for maternal and perinatal health research and surveillance in light of emerging and ongoing epidemic threats](#)

[version 1; peer review: awaiting peer review]

Veronica Pingray, Karen Klein, Juan Pedro Alonso, María Belizan, Gabriella Radice, Magdalena Babinska, Mabel Berrueta, Mercedes Bonet

Peer Reviewers Invited

Funders

Bill and Melinda Gates Foundation

World Health Organization

PUBLISHED 08 Mar 2024

Background

Maternal and perinatal health is often directly and indirectly affected during infectious disease epidemics. Yet, a lack of evidence on epidemics' impact on women and their offspring delays informed decision-making for healthcare providers, pregnant women, women in the post-pregnancy period and policy-makers. To rapidly generate evidence in these circumstances, we aim to develop a Core Outcome Set (COS) for maternal and perinatal health research and surveillance in light of emerging and ongoing epidemic threats.

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 09 Mar 2024]

[Filter: All articles]

[Informing an investment case for Japanese encephalitis vaccine introduction in Bangladesh](#)

Mariana Perez Duque, Abu Mohd Naser, Kishor K Paul, Mahmudur Rahman, Mohammad Shafiul Alam, Hasan Mohammad Al-Amin, Mohammed Ziaur Rahman, Mohammad Enayet Hossain, Repon C Paul, Stephen P Luby, Simon Cauchemez, Jessica Vanhomwegen, Emily S Gurley, Henrik Salje
medRxiv 2024.03.06.24303865; doi: <https://doi.org/10.1101/2024.03.06.24303865>

[COVID-19 Vaccination Booster Uptake Is Related to End of Pandemic Perception: Population-Based Survey in Four Provinces in Indonesia](#)

Ahmad Watsiq Maula, citra indriani, Risalia Reni Arisanti, Vincentius Arca Testamenti, Catharina Yekti Praptiningsih, Rebecca Merrill, Ansariadi Ansariadi, Tri Yunis Miko Wahyono, Atik Choirul Hidajah, RIRIS ANDONO AHMAD
medRxiv 2024.03.05.24303828; doi: <https://doi.org/10.1101/2024.03.05.24303828>

[Learning from the COVID-19 pandemic: a systematic review of mathematical vaccine prioritization models](#)

Gilberto Gonzalez-Parra, Md Shahriar Mahmud, Claus Kadelka
medRxiv 2024.03.04.24303726; doi: <https://doi.org/10.1101/2024.03.04.24303726> Revision

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 09 Mar 2024]

Selected Research

Research Article Open Access

[Impact of virtual reality on promoting understanding of research in rural Africa: The KEMRI-Wellcome Trust virtual tour of research laboratories](#)

[version 1; peer review: awaiting peer review]

Patience Kerubo Kiyuka, et al.

Background

Virtual Reality (VR) is poised to transform how science is communicated to the public. There is limited evidence of the use of VR for science education or engagement in sub-Saharan Africa. We produced a virtual reality video tour of the KEMRI-Wellcome Trust Research Programme (KWTRP) laboratories and tested its suitability as an engagement tool for secondary school students.

* * * *

[Think Tanks](#)

Brookings [to 09 Mar 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 09 Mar 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

Chatham House [to 09 Mar 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 09 Mar 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 09 Mar 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 09 Mar 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 09 Mar 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 09 Mar 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 09 Mar 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

report | Mar 7, 2024

[How Americans View the Coronavirus, COVID-19 Vaccines Amid Declining Levels of Concern](#)

Just 20% of the public views the coronavirus as a major threat to the health of the U.S. population and only 10% are very concerned about getting a serious case themselves. In addition, a relatively small share of U.S. adults (28%) say they've received an updated COVID-19 vaccine since last fall.

Rand [to 09 Mar 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Journal Article

[Lyme Disease Vaccine Attitudes and Intentions Among Parents of Children Aged 5-18 Years in the United States](#)

Two-thirds of parents would vaccinate their children against Lyme disease. Given a slight preference for monoclonal antibody over vaccine, particularly in rural areas, access to both may increase LD prevention.

Mar 6, 2024

Courtney A. Gidengil, Aaron M. Scherer, Andrew M. Parker, Amber M. Gedlinske, Shannon Fleck-Deerderian, Alison F. Hinckley, Sarah A. Hook, Megan Lindley, Grace E. Marx

Urban Institute [to 09 Mar 2024]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

World Economic Forum [to 09 Mar 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.



Public Consultations/Call for Inputs/Call for Papers

Public consultation of the Global Ethics Charter for the Protection of Healthy Volunteers in Clinical Trials

Inserm Issued 26 Feb 2024 **Comments due by March 30, 2024.**

The « Global Ethics Charter for the Protection of Healthy Volunteers in Clinical Trials » is a key deliverable of the VoIREthics initiative that was set up to promote ethical guidelines to protect healthy volunteers in biomedical research. The draft Charter, available in English, French and Spanish is open for public comments up to March 30, 2024.

Download the draft Charter (pdf, 201 Ko)

To submit your or your organization’s feedback, download the public comment document (docx, 27 Ko). Please email the completed document to hvworkshop.disc@inserm.fr

Key Information and Facilitating Understanding in Informed Consent; Draft Guidance for Sponsors, Investigators, and Institutional Review Boards

21 CFR Part 50 [Docket No. FDA-2022-D-2997] **Comments due: 04/30/2024**

SUMMARY:

This draft guidance provides recommendations related to two provisions of the revised Federal Policy for the Protection of Human Subjects (the revised Common Rule) by the U.S. Department of Health and Human Services (HHS) and identical provisions in FDA’s proposed rule “Protection of Human Subjects and Institutional Review Boards.” FDA’s proposed rule, if finalized, would harmonize certain sections of FDA’s regulations on human subject protections and institutional review boards (IRBs), to the extent practicable and consistent with other statutory provisions, with the revised Common Rule, in accordance with the 21st Century Cures Act (Cures Act). The guidance addresses the provisions of the revised Common Rule that require informed consent to begin with key information about the research and to present information in a way that facilitates understanding and identical provisions in FDA’s proposed rule.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.



Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization,

products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*